Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Bullboard - Stock Discussion Forum Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is... see more

Add To Watchlist

TSXV:ARCH - Post Discussion

Arch Biopartners Inc > Extremely Undervalued in Comparison to peers

View:

Post by Riverfolk on Oct 30, 2021 11:08am

Extremely Undervalued in Comparison to peers

The recent realization by the market has made the Arch chart look incredible, but lets no forget that we are extremely undervalued compared to our peers.

Current Market cap 141 mil US

We are waiting on Phase II Human Clinical Trial Data by a third party for a 20 billion a year unmet market.

BLU is currently 578 mil market cap for Chronic Cough (Phase 2)

VXRT is currently 888 mil market cap US Oral Vaccines

SAVA is 2 billion US market cap for Blood Cancer (Phase 2)

CYDY is 1.1 billion US market cap for Antibodies

TRIL was 2.2 billion buyout (Phase 2)

As we wait on data, there is no reason why we are not at a 600 million market cap of $9.68. We have fully patented new mechanism of action with a drug library. IMHO we will be 10x this current price if data deems it worthy.

138